Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing

Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus

(2010) Barry Rockx et al.   JOURNAL OF INFECTIOUS DISEASES

Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo.

(2010) Jessamy C Tiffen et al.   Molecular Cancer

Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission

(2009) R. L. Graham et al.   JOURNAL OF VIROLOGY

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

(2009) Lanying Du et al.   NATURE REVIEWS MICROBIOLOGY

Combination Therapy Using Chimeric Monoclonal Antibodies Protects Mice from Lethal H5N1 Infection and Prevents Formation of Escape Mutants

(2009) Mookkan Prabakaran et al.   PLoS One

Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms

(2009) Melissa M. Coughlin et al.   VIROLOGY

Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors

(2008) I-Jung Liu et al.   ANTIVIRAL RESEARCH

Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

(2008) B. Rockx et al.   JOURNAL OF VIROLOGY

Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide

(2008) B. J. Bosch et al.   JOURNAL OF VIROLOGY